Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 22c
May 9, 2016 7:46 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.06), $0.22 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $17.33 million.
Cash and cash equivalents were $78.3 million as of March 31, 2016.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More